ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Talabostat is on this study

  • The record lists it as a treatment.
  • Claude Opus 5.5 judged it tested: part of what the study tests. Nov 1, 2026, 8:22 AM UTC
  • The role rule says the same.
  • So Talabostat's page lists this study under “Testing it”.
  • The record changed after this reading. Until it is read again, the page keeps the reading and says so.
5 links0 made here, not in the record11 judgments2 judges (the rules as one: Rule based)1 record change seen1 read an older version
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govReplaced, or read an older version
Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT03910660A Trial of Talabostat(BXCL701) and Pembrolizumabin Participants WithMetastaticCastrate-Resistant ProstateCancer (mCRPC) Either SmallCell NeuroendocrineBioXcel Therapeutics IncPhase 1/Phase 2 · completedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 10 · ClinicalTrials.gov record · Version of 2026-11-10Nov 10 · Rule based · Reading set asideNov 16 · Rule based · Read againRead againCONDITIONSProstatic NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionNeuroendocrine TumorsThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseaseCarcinoma, Small CellThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termDRUGSTalabostatIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPembrolizumabIntervention entry›Nov 1 · Claude Opus 5.5 · BackgroundNov 16 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partner

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
1 version of the record seen on ClinicalTrials.gov, Nov 10 · changes seen, not judgments
Nov 1TalabostatClaude Opus 5.5TestedRead an older version
Nov 1PembrolizumabClaude Opus 5.5BackgroundReplaced
Nov 10The record itselfRule based · nightly checkReading set asideCurrent
Nov 14Prostatic NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14Neuroendocrine TumorsRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 14Carcinoma, Small CellRule based · condition-kind ruleFinest filed termCurrent
Nov 16The record itselfRule based · nightly checkRead againCurrent
Nov 16PembrolizumabClaude Opus 5.5Background · partnerCurrent
Nov 18TalabostatRule based · role ruleTestedCurrent
Nov 18PembrolizumabRule based · role ruleBackgroundAgrees
As of nowProstatic NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.

When a study changes after it was read

Every night, studies whose record changed are compared with the last reading. A change to sites or dates leaves the reading as it is; a reworded entry keeps it; a change to the treatments or conditions marks it to be read again.

Until it is read again, the page shows the last reading and says so.